시장보고서
상품코드
1663924

단백질 치료제 시장 규모, 점유율, 성장 분석 : 유형별, 용도별, 최종사용자별, 기능별, 지역별 - 산업 예측(2025-2032년)

Protein Therapeutics Market Size, Share, and Growth Analysis, By Type (Monoclonal Antibodies, Insulin), By Application (Cancer, Metabolic Disorders), By End User, By Function, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 219 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

단백질 치료제 시장 규모는 2023년 2,425억 8,000만 달러로 평가되며, 2024년 2,571억 3,000만 달러에서 2032년 4,098억 3,000만 달러로 예측 기간(2025-2032년) 동안 6.0%의 CAGR로 성장할 것으로 예상됩니다.

세계 인구의 고령화로 인해 만성질환의 유병률이 증가함에 따라, 특히 당뇨병, 자가면역질환, 암과 같은 질병을 치료할 수 있는 효율적인 단백질 치료제에 대한 수요가 증가하고 있습니다. 기존의 저분자 의약품과 달리 생물학적 제제, 특히 단클론항체는 효능, 부작용이 적고 표적 특이성이 뛰어나 인기를 끌고 있습니다. 단백질 공학 및 생명공학의 발전은 융합 단백질 및 이중특이성항체와 같은 차세대 생물학적 제제의 기술 혁신에 초점을 맞추면서 이 시장을 더욱 강화하고 있습니다. 또한, 단클론항체를 이용한 맞춤형 암 치료는 정확한 치료를 위해 점점 더 필수적인 요소가 되고 있습니다. 또한, 단백질 대체요법(PRTs)은 희귀질환 연구를 장려하는 세계 이니셔티브에 의해 큰 주목을 받고 있으며, 오리지널 바이오의약품의 특허 만료로 인한 바이오시밀러의 등장과 함께 치료 선택의 폭이 넓어지고 있습니다.

목차

소개

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 가정과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porters 분석

주요 시장 인사이트

  • 핵심성공요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

단백질 치료제 시장 규모 : 유형별

  • 시장 개요
  • 단클론항체
  • 인슐린
  • 융합 단백질
  • 인간성장호르몬
  • 에리스로포이에틴
  • 인터페론

단백질 치료제 시장 규모 : 용도별

  • 시장 개요
  • 대사장애
  • 면역질환
  • 혈액질환
  • 호르몬장애
  • 유전성 질환
  • 기타

단백질 치료제 시장 규모 : 최종사용자별

  • 시장 개요
  • 제약회사
  • 헬스케어 서비스 프로바이더
  • 조사기관
  • 학술조사기관

단백질 치료제 시장 규모 : 기능별

  • 시장 개요
  • 백신
  • 효소와 조절
  • 단백질 진단

단백질 치료제 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5개사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채용한 전략
  • 최근의 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • 기업 상세
    • 제품 포트폴리오 분석
    • 기업 부문별 점유율 분석
    • 매출 전년비 비교(2022-2024년)

주요 기업 개요

  • Johnson & Johnson(United States)
  • Roche(Switzerland)
  • Merck & Co.(United States)
  • Pfizer(United States)
  • AbbVie(United States)
  • Sanofi(France)
  • AstraZeneca(United Kingdom)
  • Novartis(Switzerland)
  • Bristol-Myers Squibb(United States)
  • Abbott Laboratories(United States)
  • GlaxoSmithKline(United Kingdom)
  • Novo Nordisk(Denmark)
  • Eli Lilly and Company(United States)
  • Amgen(United States)
  • Gilead Sciences(United States)
  • Biogen(United States)
  • Bayer(Germany)
  • Takeda Pharmaceutical Company(Japan)
  • CSL Behring(Australia)
  • Teva Pharmaceutical Industries(Israel)

결론과 제안

ksm 25.04.03

Protein Therapeutics Market size was valued at USD 242.58 billion in 2023 and is poised to grow from USD 257.13 billion in 2024 to USD 409.83 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The rising prevalence of chronic diseases, driven by an ageing global population, is fueling demand for efficient protein therapeutics, particularly to address conditions like diabetes, autoimmune disorders, and cancer. Unlike traditional small-molecule drugs, biologics, especially monoclonal antibodies, are gaining popularity due to their efficacy, fewer side effects, and targeted specificity. Advancements in protein engineering and biotechnology are further enhancing this market, with a focus on innovating next-generation biologics such as fusion proteins and bispecific antibodies. Moreover, tailored cancer therapies utilizing monoclonal antibodies are increasingly vital for precise treatment. In addition, protein replacement therapies (PRTs) are receiving significant attention, spurred by global initiatives encouraging research into rare diseases, alongside the emergence of biosimilars as original biologics' patents expire, broadening therapeutic options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

The Protein Therapeutics market is significantly driven by the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, which are becoming increasingly widespread globally. This surge in chronic illnesses is a primary catalyst for the growing demand for innovative protein-based treatments, such as biologics and monoclonal antibodies. These advanced therapeutic options offer targeted treatment capabilities, allowing for more effective management of complex medical conditions while minimizing side effects. As healthcare providers seek to address these pressing health issues, the reliance on protein therapeutics continues to expand, shaping the future of medical treatments and improving patient outcomes.

Restraints in the Protein Therapeutics Market

Despite the effectiveness of protein therapeutics, several factors hinder their widespread adoption. Chief among these is the high cost associated with these treatments, which renders them inaccessible to numerous patients. Additionally, inadequate insurance coverage complicates the financial landscape, as reimbursement levels vary significantly across different regions. This variability particularly affects patients in emerging markets, where affordability becomes a major barrier. Such economic challenges ultimately restrict market growth, limiting the potential of protein therapeutics to reach those who could benefit most from them, thereby impeding progress in this vital healthcare sector.

Market Trends of the Protein Therapeutics Market

The Protein Therapeutics market is experiencing a significant upward trend, fueled by the rising demand for personalized medicine that tailors treatments to individual genetic profiles. This shift enhances treatment efficacy while minimizing adverse effects, thereby attracting a larger patient base, particularly for oncology and autoimmune disorders. The increased focus on targeted biologics and advanced protein therapies not only caters to the specific needs of patients but also drives innovation in drug development. As healthcare providers embrace personalized approaches, investment in research and technology for protein-based therapeutics will likely intensify, positioning this market for substantial growth and advancement in the coming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Human Growth Hormone
  • Erythropoietin
  • Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Cancer
  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

Global Protein Therapeutics Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Pharmaceutical companies
  • Healthcare Service Providers
  • Research Organizations
  • Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2025-2032)

  • Market Overview
  • Vaccines
  • Enzymatic and Regulatory
  • Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2025-2032)

  • North America (Type, Application, End User, Function)
    • US
    • Canada
  • Europe (Type, Application, End User, Function)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Application, End User, Function)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Application, End User, Function)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Application, End User, Function)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Johnson & Johnson (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Behring (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제